» Articles » PMID: 7910842

Antigen-specific Activation, Tolerization, and Reactivation of the Interleukin 4 Pathway in Vivo

Overview
Journal J Exp Med
Date 1994 Jun 1
PMID 7910842
Citations 15
Authors
Affiliations
Soon will be listed here.
Abstract

The outcome of immune responses critically depends on the pattern of lymphokines secreted by CD4+ T cells. CD4+ T cells may differentiate into interleukin 2 (IL-2) and interferon gamma secreting T helper 1 (Th1)-like cells or IL-4/IL-5/IL-10 secreting Th2-like cells. However, the mechanisms that regulate production of IL-4 or other T cell lymphokines in vivo remain unknown. We use the superantigen, Staphylococcus enterotoxin A (SEA), as a model antigen to characterize the signals that regulate the production of IL-4 in vivo. Induction of IL-4 in normal CD4+ T cells required stimulation with both antigen and IL-4. SEA-specific CD4+ T cells produced large amounts of IL-4 when restimulated within 10 d after in vivo priming. Repetitive application of both signals was required to prevent downregulation of IL-4 production. Although controversy exists regarding the susceptibility of Th2-like cells to tolerogenic signals, high doses of superantigen readily abolished the capacity to produce IL-4 in both naive T cells and in T cells already primed for IL-4 production. Infection with the nematode, Nippostrongylus brasiliensis, reversed the established T cell tolerance, whereas the signals which induced IL-4 production in normal T cells, antigen and IL-4, were not capable of reversing superantigen-specific tolerance in vivo. The major parameter that correlated with the capacity of parasitic infection to break tolerance was magnitude of the lymphoproliferation seen during the course of the infection. The capacity to activate or tolerize the IL-4 pathway in an antigen-specific fashion should prove useful in the design of antigen-specific therapies for autoimmune and allergic diseases.

Citing Articles

A molecule solves psoriasis? Systemic therapies for psoriasis inducing interleukin 4 and Th2 responses.

Ghoreschi K, Mrowietz U, Rocken M J Mol Med (Berl). 2003; 81(8):471-80.

PMID: 12879154 DOI: 10.1007/s00109-003-0460-9.


Interleukin-10 expressed at early tumour sites induces subsequent generation of CD4(+) T-regulatory cells and systemic collapse of antitumour immunity.

Seo N, Hayakawa S, Takigawa M, Tokura Y Immunology. 2001; 103(4):449-57.

PMID: 11529935 PMC: 1783257. DOI: 10.1046/j.1365-2567.2001.01279.x.


Macrophages in rheumatoid arthritis.

Kinne R, Brauer R, Stuhlmuller B, Palombo-Kinne E, Burmester G Arthritis Res. 2000; 2(3):189-202.

PMID: 11094428 PMC: 130001. DOI: 10.1186/ar86.


Suppression of ongoing experimental allergic encephalomyelitis (EAE) in Lewis rats: synergistic effects of myelin basic protein (MBP) peptide 68-86 and IL-4.

Xu L, Huang Y, Yang J, van der Meide P, Link H, Xiao B Clin Exp Immunol. 2000; 120(3):526-31.

PMID: 10844533 PMC: 1905554. DOI: 10.1046/j.1365-2249.2000.01233.x.


Th1/Th2 balance in atopy.

Biedermann T, Rocken M Springer Semin Immunopathol. 2000; 21(3):295-316.

PMID: 10666775 DOI: 10.1007/BF00812259.


References
1.
Hu-Li J, OHara J, Watson C, Tsang W, Paul W . Derivation of a T cell line that is highly responsive to IL-4 and IL-2 (CT.4R) and of an IL-2 hyporesponsive mutant of that line (CT.4S). J Immunol. 1989; 142(3):800-7. View

2.
Kundig T, Schorle H, Bachmann M, Hengartner H, Zinkernagel R, Horak I . Immune responses in interleukin-2-deficient mice. Science. 1993; 262(5136):1059-61. DOI: 10.1126/science.8235625. View

3.
Mueller D, Chiodetti L, Bacon P, Schwartz R . Clonal anergy blocks the response to IL-4, as well as the production of IL-2, in dual-producing T helper cell clones. J Immunol. 1991; 147(12):4118-25. View

4.
Bandeira A, Mengel J, Coutinho A . Proliferative T cell anergy to MIs-1a does not correlate with in vivo tolerance. Int Immunol. 1991; 3(9):923-31. DOI: 10.1093/intimm/3.9.923. View

5.
Sadick M, Heinzel F, Holaday B, Pu R, Dawkins R, Locksley R . Cure of murine leishmaniasis with anti-interleukin 4 monoclonal antibody. Evidence for a T cell-dependent, interferon gamma-independent mechanism. J Exp Med. 1990; 171(1):115-27. PMC: 2187647. DOI: 10.1084/jem.171.1.115. View